Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$144.95 - $152.29 $2.82 Million - $2.96 Million
19,423 Added 73.35%
45,902 $6.94 Million
Q2 2022

Aug 12, 2022

SELL
$83.14 - $145.99 $1.54 Million - $2.7 Million
-18,522 Reduced 41.16%
26,479 $3.86 Million
Q1 2022

May 13, 2022

SELL
$110.08 - $142.92 $866,880 - $1.13 Million
-7,875 Reduced 14.89%
45,001 $5.34 Million
Q4 2021

Feb 10, 2022

BUY
$99.73 - $148.48 $2.96 Million - $4.41 Million
29,720 Added 128.35%
52,876 $7.29 Million
Q3 2021

Nov 10, 2021

SELL
$98.85 - $138.91 $166,166 - $233,507
-1,681 Reduced 6.77%
23,156 $3.22 Million
Q2 2021

Aug 10, 2021

SELL
$65.78 - $105.02 $1.05 Million - $1.68 Million
-16,031 Reduced 39.23%
24,837 $2.41 Million
Q1 2021

May 10, 2021

BUY
$64.07 - $91.75 $1.93 Million - $2.77 Million
30,188 Added 282.66%
40,868 $2.79 Million
Q4 2020

Feb 10, 2021

SELL
$65.07 - $98.24 $1.49 Million - $2.25 Million
-22,928 Reduced 68.22%
10,680 $915,000
Q3 2020

Nov 13, 2020

BUY
$59.04 - $77.95 $1.13 Million - $1.49 Million
19,137 Added 132.24%
33,608 $2.19 Million
Q2 2020

Aug 07, 2020

BUY
$29.01 - $74.23 $221,375 - $566,449
7,631 Added 111.56%
14,471 $1.06 Million
Q1 2020

May 15, 2020

SELL
$27.51 - $57.29 $1.41 Million - $2.93 Million
-51,203 Reduced 88.22%
6,840 $233,000
Q4 2019

Feb 10, 2020

SELL
$40.86 - $57.65 $2.77 Million - $3.9 Million
-67,735 Reduced 53.85%
58,043 $3.16 Million
Q3 2019

Nov 14, 2019

BUY
$37.38 - $49.47 $1.81 Million - $2.4 Million
48,518 Added 62.8%
125,778 $5.25 Million
Q2 2019

Aug 09, 2019

BUY
$39.79 - $67.01 $833,640 - $1.4 Million
20,951 Added 37.21%
77,260 $3.38 Million
Q1 2019

May 15, 2019

BUY
$34.52 - $53.29 $1.94 Million - $3 Million
56,309 New
56,309 $2.9 Million

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.18B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.